OVERVIEW

Community Practice Connections™ 18th Annual International Congress on the Future of Breast Cancer™ is organized by Physicians' Education Resource, LLC (PER).

Release Date: September 30, 2019
Expiration Date: September 30, 2020

Accreditation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Community Practice Connections™: 18th Annual International Congress on the Future of Breast Cancer™ features a review of recent clinical data guiding best practices in the treatment of patients with early-stage and advanced/metastatic breast cancer. Within the last few years, several new agents have entered the treatment armamentarium, and indications have expanded for others, resulting in continuously evolving treatment algorithms. The rapidity of these changes, combined with the volume of underlying data, creates challenges for practicing clinicians with regard to understanding how to best apply the emerging evidence to optimize outcomes for their patients. This educational activity is designed to update you on the latest data that have changed practice, or have the potential to change practice, for hormone receptor–positive, HER2-positive, and triple-negative breast cancers. In addition, this activity will explore the evolving utility of gene expression assays for guiding decision making in the clinic. Didactic summaries are accompanied by short video interviews with internationally recognized experts in the management of breast cancer. The video commentaries provide expert perspectives with regard to treatment decision points, clinical challenges, and questions commonly faced in community practice.

Benefits of Participating:
• Learn about the most recent clinical advances for patients with breast cancer.
• Hear experts discuss how they apply the latest clinical data and updated treatment guidelines to the management of their patients with breast cancer.
• Review strategies for individualizing treatment selection based on molecular biomarkers, patient comorbidities, and tumor-specific factors.
• Learn best practices for monitoring and managing adverse events associated with novel therapeutic agents.
• Gain awareness of new and emerging agents for the treatment of breast cancer, which may provide clinical trial opportunities for patients.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Individualize treatment planning for patients with breast cancer, integrating biomarker results and molecular and/or genomic assays as appropriate.
• Review the latest advances and best practices in surgery and radiation therapy in order to optimize locoregional control in patients with early-stage or locally advanced breast cancer.
• Integrate recent clinical trial results with systemic agents into personalized treatment strategies to optimize outcomes for patients with breast cancer.
• Discuss the impact of emerging data regarding investigational approaches on evolving treatment paradigms for managing breast cancer.
• Identify variances in care and planned/ongoing clinical trials that are evaluating investigational approaches in breast cancer treatment settings.